Francisco Fernández
Research Subjects
Francisco Fernández has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Curcio
Instituto Sacre Cour, Infectología Institucional SRL, Buenos Aires, Argentina
5 shared publications Daniel Curcio
Pfizer Argentina, Buenos Aires, Argentina
3 shared publications- Daniel Curcio
Pfizer S.L.U., Madrid, Spain
3 shared publications Alejandro Cane
Vaccines Medical and Scientific Affairs Lead Emerging Markets, Pfizer Inc, Buenos Aires
2 shared publicationsAlejandro Cané
Vaccines Emerging Markets, Pfizer Inc, Buenos Aires, Argentina
2 shared publicationsD. Curcio
Sanatorio San José,Infectología Institucional SRL, Buenos Aires, Argentina
2 shared publications
Latest Publications
- Open Access
- 1 March 2019
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 80, 34-45
Surgical site infection in elective clean and clean-contaminated surgeries in developing countries
- 1 March 2019
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 80, 34-45
Open AccessSurgical site infection in elective clean and clean-contaminated surgeries in developing countries
- Open Access
- 18 January 2019
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 8 (1) , 87-103
Clostridium difficile-associated Diarrhea in Developing Countries: A Systematic Review and Meta-Analysis
Introduction The prevalence of Clostridium difficile infection is rapidly increasing worldwide, but prevalence is difficult to estimate in developing countries where awareness, diagnostic resources, and surveillance protocols are limited. As diarrhea is the hallmark symptom, we conducted a systematic review and meta-analysis to determine the prevalence and incidence of C. difficile infection in patients in these regions who presented with diarrhea. Methods We conducted a systematic literature search of MEDLINE/PubMed, Scopus, and Latin-American and Caribbean Health Sciences Literature databases to identify and analyze data from recent studies providing prevalence or incidence rates of C. difficile-associated diarrhea in developing countries within four regions: Africa–Middle East, developing Asia, Latin America, and China. Our objectives were to determine the current prevalence and incidence density rates of first episodes of C. difficile-associated diarrhea in developing countries. Results Within the regions included in our analysis, prevalence of C. difficile infection in patients with diarrhea was 15% (95% CI 13–17%) (including community and hospitalized patients), with no significant difference across regions. The incidence of C. difficile infection in 17 studies including this information was 8.5 per 10,000 patient-days (95% CI 5.83–12.46). Prevalence was significantly higher in hospitalized patients versus community patients (p = 0.0227). Conclusion Our prevalence estimate of 15% is concerning; however, low awareness and inconsistent diagnostic and surveillance protocols suggest this is markedly underestimated. Enhanced awareness and management of C. difficile infection in patients with diarrhea, along with improvements in infection control and surveillance practices, should be implemented to reduce prevalence of C. difficile-associated diarrhea in developing countries. Funding Pfizer Inc.
- 18 January 2019
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 8 (1) , 87-103
Open AccessClostridium difficile-associated Diarrhea in Developing Countries: A Systematic Review and Meta-Analysis
Introduction The prevalence of Clostridium difficile infection is rapidly increasing worldwide, but prevalence is difficult to estimate in developing countries where awareness, diagnostic resources, and surveillance protocols are limited. As diarrhea is the hallmark symptom, we conducted a systematic review and meta-analysis to determine the prevalence and incidence of C. difficile infection in patients in these regions who presented with diarrhea. Methods We conducted a systematic literature search of MEDLINE/PubMed, Scopus, and Latin-American and Caribbean Health Sciences Literature databases to identify and analyze data from recent studies providing prevalence or incidence rates of C. difficile-associated diarrhea in developing countries within four regions: Africa–Middle East, developing Asia, Latin America, and China. Our objectives were to determine the current prevalence and incidence density rates of first episodes of C. difficile-associated diarrhea in developing countries. Results Within the regions included in our analysis, prevalence of C. difficile infection in patients with diarrhea was 15% (95% CI 13–17%) (including community and hospitalized patients), with no significant difference across regions. The incidence of C. difficile infection in 17 studies including this information was 8.5 per 10,000 patient-days (95% CI 5.83–12.46). Prevalence was significantly higher in hospitalized patients versus community patients (p = 0.0227). Conclusion Our prevalence estimate of 15% is concerning; however, low awareness and inconsistent diagnostic and surveillance protocols suggest this is markedly underestimated. Enhanced awareness and management of C. difficile infection in patients with diarrhea, along with improvements in infection control and surveillance practices, should be implemented to reduce prevalence of C. difficile-associated diarrhea in developing countries. Funding Pfizer Inc.
- 15 September 2018
- Published by Pro Pharma Communications International in Generics and Biosimilars Initiative Journal
- Vol. 7 (3) , 111-120
Implementing a treatment registry for a biosimilar: continuous safety surveillance of the biosimilar Bevax® (bevacizumab) in Argentina
- 15 September 2018
- Published by Pro Pharma Communications International in Generics and Biosimilars Initiative Journal
- Vol. 7 (3) , 111-120
Implementing a treatment registry for a biosimilar: continuous safety surveillance of the biosimilar Bevax® (bevacizumab) in Argentina
- Open Access
- 2 December 2016
- Published by American Society of Hematology in Blood
- Vol. 128 (22) , 3568
Pharmacovigilance of a Rituximab Biosimilar (Novex) in Argentina
INTRODUCTION Novex is a rituximab biosimilar approved in Argentina. From January 2015 to June 2016 as part of the Risk Management Plan approved by ANMAT, every treatment detected was recorded and a follow up was implemented in order to obtain safety information. The aim of this communication is to present the information gathered during this pharmacovigilance program. MATERIALS AND METHODS All treatments with at least 1 follow up point were selected and reviewed. Treatment duration until last follow up checkpoint or date of treatment finalization was recorded. We summarized demographic data (age, gender), indication distribution, treatment exposition (duration expressed in days and number of cycles received), adverse event frequency (cumulative incidence and incidence density) and distribution. RESULTS We collected 345 treatment notifications with at least 1 follow up point. Gender distribution: 53.2 % of patients were male patients. Age range was 10 to 90 years old, with a mean of 63.9 years. The indications distribution is summarized in table 1. More than 90% of them were hematological. Average treatment duration was of 235 days with a median duration of 210 days (IQR = 152 - 311). Mean number of cycles 5.5; range (1-12).During the reported period a total of 12 Individual Case Safety Reports (ICSR) were received. This represents a cumulative incidence of 3.5 %, an incidence density of 0.015 ICSR notifications per 100 days of treatment and 0.99 per 100 administered cycles. These 12 ICSR totalized 14 different diagnoses. Of them, the most frequent was Acute Infusion Related Reaction (AIRR), as expected. All AE but 1 were classified as serious (SAE) because they had at least 1 manifestation that prolonged hospitalization or endangered life. As expected, the most frequent AE notified was AIRR (5 cases), followed by cardiovascular manifestations (2 arrhythmia, 1 cardiac failure and 1 ischemic stroke), infections (1 pneumonia, 1 progressive multifocal leukoencephalopathy), neurologic (1 paresthesia), cytopenias (1 pancytopenia) and cutaneous (1 bullous dermatitis). Most of the acute manifestations occurred within the 2 initial infusions of Rituximab, as described. CONCLUSION The observed AE frequency and distribution was consistent with product specifications. No AE notified were unlisted or were notified with greater frequency than expected. Treatments registry resulted in a suitable way to detect AE that complements spontaneous reporting.
- 2 December 2016
- Published by American Society of Hematology in Blood
- Vol. 128 (22) , 3568
Open AccessPharmacovigilance of a Rituximab Biosimilar (Novex) in Argentina
INTRODUCTION Novex is a rituximab biosimilar approved in Argentina. From January 2015 to June 2016 as part of the Risk Management Plan approved by ANMAT, every treatment detected was recorded and a follow up was implemented in order to obtain safety information. The aim of this communication is to present the information gathered during this pharmacovigilance program. MATERIALS AND METHODS All treatments with at least 1 follow up point were selected and reviewed. Treatment duration until last follow up checkpoint or date of treatment finalization was recorded. We summarized demographic data (age, gender), indication distribution, treatment exposition (duration expressed in days and number of cycles received), adverse event frequency (cumulative incidence and incidence density) and distribution. RESULTS We collected 345 treatment notifications with at least 1 follow up point. Gender distribution: 53.2 % of patients were male patients. Age range was 10 to 90 years old, with a mean of 63.9 years. The indications distribution is summarized in table 1. More than 90% of them were hematological. Average treatment duration was of 235 days with a median duration of 210 days (IQR = 152 - 311). Mean number of cycles 5.5; range (1-12).During the reported period a total of 12 Individual Case Safety Reports (ICSR) were received. This represents a cumulative incidence of 3.5 %, an incidence density of 0.015 ICSR notifications per 100 days of treatment and 0.99 per 100 administered cycles. These 12 ICSR totalized 14 different diagnoses. Of them, the most frequent was Acute Infusion Related Reaction (AIRR), as expected. All AE but 1 were classified as serious (SAE) because they had at least 1 manifestation that prolonged hospitalization or endangered life. As expected, the most frequent AE notified was AIRR (5 cases), followed by cardiovascular manifestations (2 arrhythmia, 1 cardiac failure and 1 ischemic stroke), infections (1 pneumonia, 1 progressive multifocal leukoencephalopathy), neurologic (1 paresthesia), cytopenias (1 pancytopenia) and cutaneous (1 bullous dermatitis). Most of the acute manifestations occurred within the 2 initial infusions of Rituximab, as described. CONCLUSION The observed AE frequency and distribution was consistent with product specifications. No AE notified were unlisted or were notified with greater frequency than expected. Treatments registry resulted in a suitable way to detect AE that complements spontaneous reporting.
- Open Access
- 1 May 2016
- Published by Elsevier in Value in Health
- Vol. 19 (3) , A215
ECONOMIC IMPACT OF MULTI-MORBIDITY IN COMMUNITY-ACQUIRED PNEUMONIA: EXPERIENCE IN ARGENTINA
- 1 May 2016
- Published by Elsevier in Value in Health
- Vol. 19 (3) , A215
Open AccessECONOMIC IMPACT OF MULTI-MORBIDITY IN COMMUNITY-ACQUIRED PNEUMONIA: EXPERIENCE IN ARGENTINA
- Open Access
- 9 December 2015
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 2 (suppl_1)
Risk Factors Associated With Community-Acquired Pneumonia Among Hospitalized Patients: The Impact of Risk Stacking on Long-Term Mortality
Background. Increasing age and chronic underlying diseases are risk factors for community-acquired pneumonia (CAP). In terms of probability to suffer CAP, some authors have recently published that rates in immunocompetent persons with ≥2 at-risk (AR) conditions (multimorbidity or risk stacking [RS]) were similar or higher than rates in persons with high risk (HR) conditions (immunocompromised). We conducted a hospitalized-based, retrospective cohort study in order to evaluate the long-term mortality impact of risk stacking in patients ≥18 years-old with CAP.
- 9 December 2015
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 2 (suppl_1)
Open AccessRisk Factors Associated With Community-Acquired Pneumonia Among Hospitalized Patients: The Impact of Risk Stacking on Long-Term Mortality
Background. Increasing age and chronic underlying diseases are risk factors for community-acquired pneumonia (CAP). In terms of probability to suffer CAP, some authors have recently published that rates in immunocompetent persons with ≥2 at-risk (AR) conditions (multimorbidity or risk stacking [RS]) were similar or higher than rates in persons with high risk (HR) conditions (immunocompromised). We conducted a hospitalized-based, retrospective cohort study in order to evaluate the long-term mortality impact of risk stacking in patients ≥18 years-old with CAP.
- Open Access
- 6 May 2010
- Published by Wiley in Pediatric Pulmonology
- Vol. 45 (6) , 619-625
Viruses and atypical bacteria associated with asthma exacerbations in hospitalized children
Objectives and Working Hypothesis: To evaluate the prevalence of respiratory viruses Mycoplasma pneumoniae and Chlamydophila pneumoniae and gain insight into their seasonal circulation pattern in children with acute asthma exacerbations in a temperate southern hemisphere region.Study Design: Patients hospitalized between 3 months and 16 years of age were included in a 1‐year prospective, observational, cross‐sectional study. Respiratory secretions were collected and the presence of different viruses and atypical bacteria analyzed by immunofluorescence and polymerase chain reaction.Results: Two hundred nine patients (118 females) aged (mean ± SD) 4.4 ± 4 years were included. A potential causative agent was detected in 78% of the patients. The most frequently detected viruses were respiratory syncytial virus (HRSV) (n = 85; 40%) and rhinovirus (HRV) (n = 52; 24.5%); M. pneumoniae and C. pneumoniae were detected in 4.5% and 2% of the cases, respectively. Patients with HRSV (vs. HRV) were hospitalized for a longer time (6.7 vs. 5.2 days, P = 0.012), required more days of oxygen supply (5.1 vs. 3.4, P = 0.005), had a longer duration of the exacerbation before hospitalization (3.6 vs. 1.9 days, P = 0.001) and were younger (3.7 vs. 5.1 years, P = 0.012). Three peaks of admissions were observed. A first peak (early autumn) caused by HRV, a second peak (winter) caused mainly by HRSV and a third one (spring), caused by HRSV, an increase in HMPV together with a second outbreak of HRV.Conclusions: Children with an acute asthma exacerbation presented a high prevalence of respiratory viruses. Most hospitalizations corresponded to seasonal increases in prevalence of HRV and HRSV. Pediatr Pulmonol. 2010; 45:619–625.
- 6 May 2010
- Published by Wiley in Pediatric Pulmonology
- Vol. 45 (6) , 619-625
Open AccessViruses and atypical bacteria associated with asthma exacerbations in hospitalized children
Objectives and Working Hypothesis: To evaluate the prevalence of respiratory viruses Mycoplasma pneumoniae and Chlamydophila pneumoniae and gain insight into their seasonal circulation pattern in children with acute asthma exacerbations in a temperate southern hemisphere region.Study Design: Patients hospitalized between 3 months and 16 years of age were included in a 1‐year prospective, observational, cross‐sectional study. Respiratory secretions were collected and the presence of different viruses and atypical bacteria analyzed by immunofluorescence and polymerase chain reaction.Results: Two hundred nine patients (118 females) aged (mean ± SD) 4.4 ± 4 years were included. A potential causative agent was detected in 78% of the patients. The most frequently detected viruses were respiratory syncytial virus (HRSV) (n = 85; 40%) and rhinovirus (HRV) (n = 52; 24.5%); M. pneumoniae and C. pneumoniae were detected in 4.5% and 2% of the cases, respectively. Patients with HRSV (vs. HRV) were hospitalized for a longer time (6.7 vs. 5.2 days, P = 0.012), required more days of oxygen supply (5.1 vs. 3.4, P = 0.005), had a longer duration of the exacerbation before hospitalization (3.6 vs. 1.9 days, P = 0.001) and were younger (3.7 vs. 5.1 years, P = 0.012). Three peaks of admissions were observed. A first peak (early autumn) caused by HRV, a second peak (winter) caused mainly by HRSV and a third one (spring), caused by HRSV, an increase in HMPV together with a second outbreak of HRV.Conclusions: Children with an acute asthma exacerbation presented a high prevalence of respiratory viruses. Most hospitalizations corresponded to seasonal increases in prevalence of HRV and HRSV. Pediatr Pulmonol. 2010; 45:619–625.
- 1 February 2009
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 21 (1) , 58-62
Late Onset Ventilator-Associated Pneumonia Due to Multidrug-Resistant Acinetobacter spp.: Experience with Tigecycline
The aim of the study was to evaluate the clinical success rate of 73 patients with ventilator-associated pneumonia (VAP) caused by multidrug-resistant (MDR)-Acinetobacter spp. treated with tigecycline in seven intensive Care Units in Argentina and to determine which predictor variables were significant in this context. Clinical success in our patients was 69.86% (Ci= 58.65-81.07%) 51/73, without significant differences between patients with VAP due to MDR-Acinetobacter spp. carbapenem-susceptible or carbapenem-resistant and only susceptible to colistin, minocyline and tigecycline (70% 44/73 vs. 69% 29/73 respectively, p=0.9006), and between patients who received 48h of prior antibiotics (73.3% 22/30 vs 67.4% 29/43 respectively, p=0.7791). Age >67 and using other method than BAL for respiratory sampling were identified as predicting variables for negative clinical outcome. Our results suggest that tigecycline may be an acceptable alternative for therapy in patients with VAP caused by MDR-Acinetobacter spp. Nevertheless, only controlled clinical trials will provide the evidence to support approval for new indications.
- 1 February 2009
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 21 (1) , 58-62
Late Onset Ventilator-Associated Pneumonia Due to Multidrug-Resistant Acinetobacter spp.: Experience with Tigecycline
The aim of the study was to evaluate the clinical success rate of 73 patients with ventilator-associated pneumonia (VAP) caused by multidrug-resistant (MDR)-Acinetobacter spp. treated with tigecycline in seven intensive Care Units in Argentina and to determine which predictor variables were significant in this context. Clinical success in our patients was 69.86% (Ci= 58.65-81.07%) 51/73, without significant differences between patients with VAP due to MDR-Acinetobacter spp. carbapenem-susceptible or carbapenem-resistant and only susceptible to colistin, minocyline and tigecycline (70% 44/73 vs. 69% 29/73 respectively, p=0.9006), and between patients who received 48h of prior antibiotics (73.3% 22/30 vs 67.4% 29/43 respectively, p=0.7791). Age >67 and using other method than BAL for respiratory sampling were identified as predicting variables for negative clinical outcome. Our results suggest that tigecycline may be an acceptable alternative for therapy in patients with VAP caused by MDR-Acinetobacter spp. Nevertheless, only controlled clinical trials will provide the evidence to support approval for new indications.
- Open Access
- 18 July 2008
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 62 (5) , 1166-1167
Comment on: Effect of different Mueller-Hinton agars on tigecycline disc diffusion susceptibility for Acinetobacter spp.
- 18 July 2008
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 62 (5) , 1166-1167
Open AccessComment on: Effect of different Mueller-Hinton agars on tigecycline disc diffusion susceptibility for Acinetobacter spp.
- 1 June 2008
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 46 (11) , 1797-1798
Tigecycline for Acinetobacter baumannii infection: other considerations.
- 1 June 2008
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 46 (11) , 1797-1798
Tigecycline for Acinetobacter baumannii infection: other considerations.